Regulatory compliance – Page 36

Validation gaps identified during change control – preventing repeat validation findings

Addressing Validation Gaps in Change Control to Prevent Recurring Findings Validation gaps identified during change control can significantly hinder pharmaceutical manufacturing compliance and efficiency. When these gaps remain unaddressed, they…

Electronic signatures misused during compliance audit – CAPA and revalidation strategy

Addressing Misuse of Electronic Signatures in Compliance Audits: A Comprehensive Playbook In today’s highly regulated pharmaceutical landscape, the efficacy of electronic signatures during compliance audits is critical. Misuse of electronic…

Inadequate worst-case selection during lifecycle management – preventing repeat validation findings

“`html Mitigating Inadequate Worst-Case Selection in Lifecycle Management: A Practical Playbook Pharmaceutical manufacturing and quality control processes are complex and require meticulous attention to detail. One recurring issue is inadequate…

GLP study documentation gaps during regulatory inspection – preventing repeat GLP findings

Addressing GLP Study Documentation Deficiencies During Regulatory Inspections In the pharmaceutical industry, ensuring compliance with Good Laboratory Practices (GLP) is essential for maintaining product integrity and regulatory compliance. GLP study…

Record retention failures during system operation – CAPA and revalidation strategy

Managing Record Retention Failures During Operational Systems: A Strategic Playbook Failures in record retention during system operations can disrupt processes, hinder compliance, and potentially lead to regulatory sanctions. For pharmaceutical…

Inadequate worst-case selection during site expansion – CAPA and revalidation strategy

Addressing Inadequate Worst-Case Selection: A Playbook for Site Expansion CAPA and Revalidation In the fast-paced environment of pharmaceutical manufacturing, adequate planning and rigorous validation are essential, especially during site expansions.…

Record retention failures during system upgrade – inspection evidence requirements

Addressing Record Retention Failures During System Upgrades: An Inspection-Ready Playbook In the pharmaceutical industry, system upgrades are a critical part of maintaining compliance and operational efficiency. However, these transitions can…

Requalification overdue during change control – CAPA and revalidation strategy

Managing Requalification Delays Amid Change Control – A Pragmatic CAPA Approach The pharmaceutical industry continually faces challenges related to maintaining compliance with Good Manufacturing Practices (GMP) and meeting regulatory expectations.…

Electronic signatures misused during compliance audit – risk-based ERES remediation

Addressing the Misuse of Electronic Signatures During Compliance Audits: A Practical Playbook In the dynamic landscape of pharmaceutical manufacturing and quality compliance, the misuse of electronic signatures during audits poses…

CSV compliance weak during change control – risk-based validation alignment

Enhancing CSV Compliance During Change Control for Effective Risk-Based Validation In the fast-paced world of pharmaceutical manufacturing, maintaining compliance with Computer System Validation (CSV) during change control processes presents a…

Archival process non-compliant during study reconstruction – CAPA for GLP system gaps

Dealing with Archival Process Non-Compliance During Study Reconstruction: A Comprehensive CAPA Playbook In the realm of pharmaceutical manufacturing and laboratory practices, ensuring compliance with Good Laboratory Practices (GLP) is paramount,…

Record retention failures during system upgrade – preventing repeat Part 11 findings

Addressing Record Retention Failures During System Upgrades to Prevent Part 11 Findings In the ever-evolving landscape of pharmaceutical manufacturing, system upgrades can inadvertently lead to record retention failures, posing significant…